Clinical Trial

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

Study acronym: HOPE-Focus
Recruiting
View on ClinicalTrials.gov →
Summary
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.
Trial Details
NCT Number NCT06991946
Lead Sponsor SOLTI Breast Cancer Research Group
Collaborators: Roche Farma, S.A, Menarini Group, AstraZeneca, Pfizer, Eli Lilly and Company
Conditions Metastatic Breast Cancer
Enrollment 300 participants
Start Date 2025-05-20
Primary Completion 2027-05-20 (estimated)
Study Completion 2030-05-20 (estimated)
Updated on ClinicalTrials.gov 2025-05-28